lisocabtagene maraleucel
Some patients whose CLL turned into lymphoma had durable responses on autologous cell therapies, according to a retrospective analysis featured at the ASH annual meeting.
FDA Accepts BMS's sBLA for Breyanzi in Certain Leukemias, Lymphomas
BMS is seeking to expand Breyanzi's indication to include chronic lymphocytic leukemia and small lymphocytic lymphoma patients.
Executives noted that its two recent acquisitions, Mirati Therapeutics and Turning Point Therapeutics, underscore its shift away from immunotherapy.
During a call to discuss its Q2 financial performance, BMS executives discussed plans to make up for the firm's top-selling cancer drug, Opdivo, losing exclusivity by the end of the decade.
Bristol Myers Squibb's Breyanzi Nets Second-Line Lymphoma Approval in Europe
The European Commission approved the autologous CAR T-cell therapy for relapsed lymphoma patients following first-line chemo-immunotherapy.